FDA warning thrashes Indian drugmaker for filthy plant, data falsification

An FDA warning letter has noted a long list of problems at Alchymars' API complex in India. (FDA)

An Indian drugmaker has halted production of a couple of APIs for the U.S. after FDA inspectors found it was falsifying data at its manufacturing complex near Tamil Nadu, India. That was just the beginning of the problems.

The warning letter for Alchymars ICM was issued two weeks ago after a September inspection uncovered a host of problems including filthy areas, equipment that was badly in need of repair and a quality-control unit that had failed to inspect customer complaints thoroughly. Some of the observations were repeats from an inspection two years earlier.

The FDA acknowledged that the company had agreed to quit producing some products, bring in a consultant to help with data integrity and do a risk assessment of the products it has shipped to the U.S., but it was not enough to keep the FDA from issuing the warning letter. The FDA said the company clearly doesn’t know how to meet FDA standards.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Repeated deficiencies demonstrate that your facility’s oversight and control over the manufacture of drugs is inadequate,” the warning letter said. “Because you failed to correct repeat deviations, we strongly recommend engaging a consultant qualified to evaluate your operations, and assist your firm in meeting CGMP requirements.”

Besides the need to get its data reporting in order, it said a consultant is needed to rework the water system in the complex. Inspectors noted that the company was drastically underreporting colony-forming units on media plates used to test water, including water used to make the API “for sterile injectable dosage forms.”

On top of that, washrooms often didn’t have hot water, soap, or hand-drying equipment, an issue that had been noted two years prior.  

Suggested Articles

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.

What challenges continue to plague the pharmaceutical industry for almost a decade? Check out this remarkable innovation in glass science that may be the…

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.